Continuous versus intermittent nebulized terbutaline: plasma levels and effects

Area of Science:

• Pharmacology
• Pediatric Pulmonology
• Clinical Trials

Background:

• Acute asthma management in children often involves beta-2 agonists.
• Nebulized terbutaline is a common treatment, administered either continuously or intermittently.
• Understanding the comparative efficacy and safety of these administration methods is crucial.

Purpose of the Study:

• To compare continuous versus intermittent nebulization of terbutaline in pediatric asthma patients.
• To determine differences in plasma terbutaline concentrations between the two methods.
• To assess adverse cardiovascular effects associated with each nebulization technique.

Main Methods:

• A randomized, double-blind clinical trial involving 16 children (6-16 years) with acute asthma.
• Administration of 16 mg terbutaline over 8 hours, either continuously or intermittently (4 mg every 2 hours).
• Monitoring of plasma terbutaline concentrations, heart rate, blood pressure, CPK-MB levels, and Holter recordings.

Main Results:

• Peak plasma terbutaline concentrations were similar for both continuous (4.7 ng/ml) and intermittent (5.1 ng/ml) nebulization.
• Maximum heart rate increases were comparable between the intermittent and continuous groups.
• No serious adverse myocardial complications were observed in either treatment group.

Conclusions:

• Continuous nebulization of terbutaline yields similar plasma concentrations as intermittent nebulization.
• Both methods result in comparable cardiovascular physiological responses.
• Continuous nebulization is a viable alternative to intermittent nebulization for terbutaline administration in acute pediatric asthma.